Home - Chinese Clinical Oncology

Join us at the 103rd Annual Meeting of American Association for Thoracic Surgery (AATS)

The 103rd Annual Meeting of American Association for Thoracic Surgery (AATS) is going to be held at the Los Angeles Convention Center, Los Angeles, CA, USA, from May 6 to 9, 2023: https://events.aats.org/am23.

This time, CCO as well as its sister journals and books published by AME Publishing Company will be on display during this exciting academic event! We would like to seize this great opportunity to meet our authors, editorial board members and readers.

Pre- and Post-operative Treatment for Pancreatic Cancer

This series on “Pre- and Post-operative Treatment for Pancreatic Cancer” is edited by Dr. Yoji Kishi from Department of Surgery, National Defense Medical College Hospital, Tokorozawa, Japan.

CCO Annual Report (2022)

We are glad to present a brief introduction of CCO’s progress in 2022 here. CCO grew steadily and published 51 papers last year, including 32 Review Articles and 4 Original Articles in total. According to the Google Analytics, CCO journal website had an increasing number of pageviews (all together 204,057 visitors worldwide and 345,615 pageviews in 2022). Two special series have been published, and four special series are ongoing.

Progress and Future Direction to Treat Advanced Gastric Cancer (Ongoing)

This series on “Progress and Future Direction to Treat Advanced Gastric Cancer” is edited by Prof. Yasuhide Yamada from Comprehensive Cancer Center, National Center for Global Health and Medicine, Japan.

Inflammatory Breast Cancer

This series on "Inflammatory Breast Cancer" is edited by Professor Naoto T. Ueno from Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, USA.

Chinese Clinical Oncology is going to receive its first impact factor in June 2023

According to the latest news of Web of Science, Clarivate Analytics on July 26, 2022, in the 2023 release of the Journal Citation Report™, all Web of Science Core Collection™ journals will receive a Journal Impact Factor (JIF)™. This means expanding the JIF from Science Citation Index Expanded (SCIE)™ and Social Science Citation Index (SSCI)™ to include journals from the Arts and Humanities Citation Index (AHCI)™ and the multidisciplinary Emerging Sources Citation Index (ESCI)™.

Interview with Prof. Rimas V. Lukas: discussion with an academic neuro-oncologist

Photo of Prof. Rimas V. Lukas.

Interviews with Outstanding Authors (2022)

In 2022, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

Unresolved Issues in Pancreatic Cancer

This series on "Unresolved Issues in Pancreatic Cancer" is edited by Professor Savio George Barreto from Hepatobiliary & Oesophagogastric Unit, Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia; College of Medicine & Public Health, Flinders University, South Australia, Australia.

Hepatobiliary and Pancreatic Cancers: an update of surgical treatments (Ongoing)

This series on "Hepatobiliary and Pancreatic Cancers: an update of surgical treatments" is edited by Professor Giovanni Battista Levi Sandri from Department of General Surgery and Transplantation, San Camillo Forlanini Hospital, Rome, Italy.

‹ ›

Vol 12, No 2 (April, 2023)

About cco

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@thecco.net
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial Commentary

Pembrolizumab for second line treatment of advanced hepatocellular carcinoma—who would benefit?

Morten Ladekarl

PDF Pages: 10 Full Text (162) COI Form Open Access

Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE)

Paula Fernández-Palanca, José L. Mauriz

PDF Pages: 11 Full Text (211) COI Form Open Access

Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer?

Jeanny B. Aragon-Ching

PDF Pages: 12 Full Text (172) COI Form Open Access

Review Article

A narrative review of intrahepatic cholangiocarcinoma: a surgical curative option

Fabio Melandro, Riccardo Aurelio Nasto, Michael Ginesini, Emanuele Balzano, Maria Lucia Bindi, Davide Ghinolfi, Quirino Lai

PDF Pages: 13 Full Text (213) Reporting Checklist COI Form Open Access

Targeted therapies in advanced biliary tract cancers—a narrative review

Michael LaPelusa, Thatcher Heumann, Laura Goff, Rajiv Agarwal

PDF Pages: 14 Full Text (164) Reporting Checklist COI Form Open Access

Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review

Luke Bressler, Natalie Bath, Ashish Manne, Eric Miller, Jordan M. Cloyd

PDF Pages: 15 Full Text (235) Reporting Checklist Peer Review File COI Form Open Access

The robotic future of minimally invasive cytoreduction and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies

Joanna Ortega, Theofano Orfanelli, Edward Levine, Ioannis T. Konstantinidis

PDF Pages: 16 Full Text (178) Peer Review File COI Form Open Access

Image-guided percutaneous locoregional therapies for hepatocellular carcinoma

Olivier Chevallier, Ken Zhao, Brett Marinelli, Hooman Yarmohammadi

PDF Pages: 17 Full Text (317) Peer Review File COI Form Open Access

Single cell sequencing of neutrophils demonstrates phenotypic heterogeneity and functional plasticity in health, disease, and cancer

Alistair S. McLaren, Rana Fetit, Colin S. Wood, John Falconer, Colin W. Steele

PDF Pages: 18 Full Text (352) Peer Review File COI Form Open Access

The emerging role for CAR T cells in solid tumor oncology

Sebastian Klobuch, Tom T. P. Seijkens, John B. A. G. Haanen

PDF Pages: 19 Full Text (463) Peer Review File COI Form Open Access

Guidelines and Expert Consensus

Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)

Primary Liver Cancer Diagnosis Treatment Expert Panel

Editorials

EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy

Jair Bar, Damien Urban, Roni Borshtein, Hovav Nechushtan, Amir Onn

Review Articles

Colorectal cancer screening: are stool and blood based tests good enough?

Chung-Wah Wu, Joseph Jao-Yiu Sung

The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention

Patrick A. Ott, F. Stephen Hodi

Current status and future direction of chemotherapy for pancreatic cancer

Junji Furuse, Fumio Nagashima

Molecular therapy for gastric cancer

Yasuhide Yamada

The future of clinical research in oncology: where are we heading to?

Denis Lacombe, Yan Liu

A review of hepatocellular carcinoma (HCC) staging systems

Somasundaram Subramaniam, Robin K. Kelley, Alan P. Venook

Emerging therapies for pancreas neuroendocrine cancers

Ali R. Mahjoub, Eileen M. O’Reilly

Prevention of colorectal cancer and dietary management

Ningqi Hou, Dezheng Huo, James J. Dignam

Review Article

Staging and response assessment in lymphomas: the new Lugano classification

Bruce D. Cheson

An overview of the NCI precision medicine trials—NCI MATCH and MPACT

Khanh Do, Geraldine O’Sullivan Coyne, Alice P. Chen

Cost-comparativeness of proton versus photon therapy

Vivek Verma, Chirag Shah, Jean-Claude M. Rwigema, Timothy Solberg, Xiaofeng Zhu, Charles B. Simone II

An overview of the design and conduct of the BATTLE trials

Suyu Liu, J. Jack Lee

Genetic and epigenetic landscape of nasopharyngeal carcinoma

Wei Dai, Hong Zheng, Arthur Kwok Leung Cheung, Maria Li Lung

The inflammatory microenvironment in brain metastases: potential treatment target?

Anna S. Berghoff, Matthias Preusser

BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management

Elisabeth Livingstone, Lisa Zimmer, Julia Vaubel, Dirk Schadendorf

Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations

Lorena Marcano-Bonilla, Essa A. Mohamed, Taofic Mounajjed, Lewis R. Roberts

Toxicity of checkpoint inhibitors

Rafael Aron Schmerling

Advances in systemic treatment for nasopharyngeal carcinoma

Wan-Ling Tan, Eng-Huat Tan, Darren Wan-Teck Lim, Quan-Sing Ng, Daniel Shao-Weng Tan, Amit Jain, Mei-Kim Ang

Immunotherapy for nasopharyngeal cancer—a review

Amit Jain, Whay Kuang Chia, Han Chong Toh

Systemic therapies for melanoma brain metastases: which drug for whom and when?

Sangeetha Ramanujam, Dirk Schadendorf, Georgina V. Long

Guidelines and Expert Consensus

Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)

Primary Liver Cancer Diagnosis Treatment Expert Panel

Review Articles

A review of hepatocellular carcinoma (HCC) staging systems

Somasundaram Subramaniam, Robin K. Kelley, Alan P. Venook

Features and treatment options of Chinese hepatocellular carcinoma

Qiong Wu, Shu-Kui Qin

Statistics in Oncology Clinical Trials

Biomarker based clinical trial design

Richard Simon

Adaptive clinical trial designs in oncology

Yong Zang, J. Jack Lee

Original Article

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments

Laura E. Johnson, Jordan T. Becker, Jason A. Dubovsky, Brian M. Olson, Douglas G. McNeel

Review Article

The spectrum of clinical trials aiming at personalizing medicine

Christophe Le Tourneau, Maud Kamal, Marie Alt, Loic Verlingue, Vincent Servois, Marie-Paule Sablin, Nicolas Servant, Xavier Paoletti

Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine

Sumithra J. Mandrekar, Daniel J. Sargent

From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer

Sophie Doisneau-Sixou, Nadia Harbeck

Melanoma adjuvant therapy

Prashanth M. Thalanayar, Sanjiv S. Agarwala, Ahmad A. Tarhini

Genotyping of cutaneous melanoma

Isabella C. Glitza, Michael A. Davies

Treatment of KIT-mutated metastatic mucosal melanoma

Kevin B. Kim, Anas Alrwas

New approaches in primary central nervous system lymphoma

Eleanor Fraser, Katherine Gruenberg, James L. Rubenstein

Molecular and clinical implementations of ovarian cancer mouse avatar models

Amira A. Zayed, Sumithra J. Mandrekar, Paul Haluska

An overview of the design and conduct of the BATTLE trials

Suyu Liu, J. Jack Lee

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials

Ryan S. Alden, Sumithra J. Mandrekar, Geoffrey R. Oxnard

Risk- and response-adapted strategies for the management of Hodgkin lymphoma

Marcus Remer, Peter W. M. Johnson

Prognostic scores for brain metastasis patients: use in clinical practice and trial design

Vyshak Alva Venur, Manmeet S. Ahluwalia

Strategies for preservation of memory function in patients with brain metastases

Nicholas B. Dye, Vinai Gondi, Minesh P. Mehta

Management of neoplastic meningitis

Patrick Roth, Michael Weller

Design and statistical principles of the SHIVA trial

Xavier Paoletti, Bernard Asselain, Maud Kamal, Nicolas Servant, Philippe Huppé, Ivan Bieche, Christophe Le Tourneau

Autologous tracheal replacement for cancer

Dominique Fabre, Elie Fadel, Sacha Mussot, Frederic Kolb, Nicolas Leymarie, Olaf Mercier, Thierry Le Chevalier, Philippe G. Dartevelle

The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice

Jean Bao, Cory Donovan, Alice Chung, Armando E. Giuliano

HER2-positive breast cancer, how far away from the cure?—on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients

Ning Liao

Training of breast surgical oncologists

Mediget Teshome, Henry M. Kuerer

The way to precision medicine of our team

Fengrui Xu, Xiaodi Wang, Zefei Jiang

Genetic testing for hereditary breast cancer in Asia—moving forward

Ava Kwong

Editorials

Can EGFR mutation status evolve with chemotherapy?

Eric S. Kim, David J. Stewart, Alok A. Khorana

Meta-Analysis

Risk of venous thromboembolism with the erythropoiesisstimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials

Ping Zhan, Qin Wang, Qian Qian, Li-Ke Yu

Review Articles

Prevention of colorectal cancer and dietary management

Ningqi Hou, Dezheng Huo, James J. Dignam

Stage II colon cancer

David N. Church, Rachel Midgley, David J. Kerr

Mining the ACCENT database: a review and update

Lindsay A. Renfro, Qian Shi, Daniel J. Sargent

Status of hepatocellular carcinoma in South Korea

Seung Kew Yoon, Hoo Geun Chun

Statistics in Oncology Clinical Trials

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation

Lindsay A. Renfro, Christina M. Coughlin, Axel M. Grothey, Daniel J. Sargent

Adaptive clinical trial designs in oncology

Yong Zang, J. Jack Lee

Statistical aspect of translational and correlative studies in clinical trials

Herbert Pang, Xiaofei Wang

Updates on Surgical Oncology

Clinical trials in lung cancer surgery and research cooperation

Wen-Zhao Zhong, Hao-Ran Zhai, Yi-Long Wu

Below are the latest Chinese Clinical Oncology articles published online ahead of print publication.

Review Article

FLOT or CROSS for gastroesophageal junction cancers—is the debate over yet?

Bushra Shariff, Rutika Mehta

Published online: 25 May 2023

Editorial

The future is here—targeted therapies are coming of age in biliary tract cancers

Daniel Neureiter, Matthias Ocker

Published online: 15 May 2023

Original Article

Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis

Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J. Ernst, Lida A. Mina

Published online: 15 May 2023

Editorial Commentary

Overview of late complications of radiation therapy in uveal melanoma

Andrew J. Wong, Amy C. Schefler, Bin S. Teh

Published online: 09 May 2023

Editorial Commentary

Re-ORIENT-ing antitumor immunity in EGFR-mutant non-small cell lung cancer: are antiangiogenics the key?

Aaron J. Franke, Erin L. Schenk

Published online: 25 April 2023

Journal Highlight more

The Chinese Clinical Oncology, indexed in MEDLINE/PubMed, ESCI, is an open-access, peer-reviewed medical journal, providing current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention and technical advances related to cancer.

Indexing

In PubMed/MEDLINE

Membership

Publishing Information

Chinese Clinical Oncology is published by AME Publishing Company

The official journal of Society for Translational Medicine (STM), Hong Kong

About cco

Manuscript Submission

AME Editing Service

Reprint & Permission

Contact us

General editorial enquiries:

Copyright related contact:

Commercial Sales contact (Reprints, advertising, etc.):

Editorial Commentary

Review Article

Guidelines and Expert Consensus

Editorials

Review Articles

Review Article

Guidelines and Expert Consensus

Review Articles

Statistics in Oncology Clinical Trials

Original Article

Review Article

Editorials

Meta-Analysis

Review Articles

Statistics in Oncology Clinical Trials

Updates on Surgical Oncology

Indexing

Membership

Publishing Information